BOBA Compounds Regulate Nerve Regeneration and Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain often result in haphazard synapse connections due to axonal outgrowth, leading to persistent pain, and there is a need for effective compounds that can both prevent and treat this condition by addressing inflammatory pathways.
Innovation Solution
The development of substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds (BOBA compounds) that cause axonal outgrowth while downregulating inflammatory pathways, thereby treating and preventing neuropathic pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments promote axonal outgrowth to repair nerve damage, then nerve regeneration is improved, but haphazard synapse connections occur leading to persistent pain
Solution Approach 1:
The patent introduces a specific compound structure (4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid with specific substituents) as an intermediary agent that mediates between axonal outgrowth promotion and synapse connection accuracy. This compound acts as a selective modulator that enables nerve regeneration while preventing the formation of incorrect synapse connections, thereby resolving the contradiction between regeneration quality and pain prevention
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of the core benzoic acid compound through specific substituents (R1-R6 groups) to optimize the balance between promoting axonal outgrowth and ensuring proper synapse formation. By adjusting molecular parameters such as substituent types and positions, the compound achieves selective action on nerve regeneration processes while avoiding harmful synapse misconnections
2Object-generated harmful factors
If anti-inflammatory pathways are downregulated to treat neuropathic pain, then pain mediation is reduced, but inflammatory response control becomes more complex
Solution Approach 1:
The patent applies segmentation by targeting specific inflammatory pathways (such as NF-κB, MAPK, or other pain-mediated inflammatory cascades) individually through the designed compound structure. Rather than attempting to control all inflammatory responses simultaneously, the compound selectively modulates specific inflammatory mediators involved in neuropathic pain, thereby reducing pain while maintaining manageable complexity in pathway regulation
Solution Approach 2:
The patent converts the harmful inflammatory response into a beneficial therapeutic effect by designing a compound that selectively downregulates inflammatory pathways responsible for pain mediation. The compound transforms the harmful inflammatory cascade into a controlled, therapeutic anti-inflammatory action that reduces neuropathic pain without requiring complex external regulation mechanisms
Data Source
AI summary
The present invention pertains generally to the field of therapy. More specifically, the present invention pertains to certain substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds (collectively referred to herein as BOBA compounds), and pharmaceutical compositions comprising those compounds, for use in a method of treatment or prevention of neuropathic pain. (Formula (A))